You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 51 No. 8, August 1994 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Articles
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Carbamazepine Increases Cerebrospinal Fluid Thyrotropin-Releasing Hormone Levels in Affectively Ill Patients

Lauren B. Marangell, MD; Mark S. George, MD; Garth Bissette, PhD; Peggy Pazzaglia, MD; Teresa Huggins, PhD; Robert M. Post, MD

Arch Gen Psychiatry. 1994;51(8):625-628.


Abstract

Background
Thyrotropin-releasing hormone is an endogenous tripeptide with endocrine-independent neurophysiologic properties that may be relevant to affective or seizure disorders. We studied the effect of carbamazepine, which has both mood-stabilizing and anticonvulsant properties, on cerebrospinal fluid thyrotropin-releasing hormone levels in affectively ill patients.

Method
Paired cerebrospinal fluid samples were collected from nine inpatients with mood disorders, both while medication free and while taking carbamazepine for an average of longer than 1 month at 950 mg/d, achieving blood levels of 8.8 mg/L.

Results
Carbamazepine treatment was consistently and significantly associated with increased cerebrospinal fluid thyrotropin-releasing hormone levels (P<.0001).

Conclusion
As carbamazepine-induced increases in thyrotropin-releasing hormone levels could be relevant to either its psychotropic or anticonvulsant properties, further clinical and preclinical investigation of this finding appears indicated.



Author Affiliations

From the Biological Psychiatry Branch, National Institute of Mental Health, Bethesda, Md (Drs Marangell, George, Pazzaglia, Huggins, and Post); and Department of Psychiatry, Duke University Medical Center, Durham, NC (Dr Bissette). Dr Marangell is now with the Department of Psychiatry, Baylor College of Medicine, Houston, Tex.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

CSF Thyrotropin-Releasing Hormone Gender Difference: Implications for Neurobiology and Treatment of Depression
Frye et al.
J. Neuropsychiatry Clin. Neurosi. 1999;11:349-353.
ABSTRACT | FULL TEXT  

Effects of Intrathecal Thyrotropin-Releasing Hormone (Protirelin) in Refractory Depressed Patients
Marangell et al.
Arch Gen Psychiatry 1997;54:214-222.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1994 American Medical Association. All Rights Reserved.